Canadian VC Market Sees Increased Capital Concentration in 2025
Canadian venture capital investment reached $8 billion across 571 deals in 2025, according to the Canadian Venture Capital Association (CVCA). This reflects a trend of capital concentration, with larger deals dominating the landscape. Just 26 megadeals accounted for two-thirds of the total investment, highlighting a narrowing focus on fewer companies.
The CVCA report indicates a 12% decline in deal flows from the previous year, yet the overall deployed capital was only 6% lower than in 2024. This shift resulted in an average deal size increase of 6% to over $14 million. The trend mirrors the US market, where similar patterns of capital concentration have been observed.
Market Trends and Implications
The report also highlights a challenging environment for Canadian VC fundraising, with 2025 marking the lowest fundraising year since 2016. The number of exits dropped to 29, all through mergers and acquisitions, as companies avoided the chilly IPO market. This led to an increased focus on secondary transactions, with $1.3 billion raised, including significant rounds by Jane Software and StackAdapt.
Late-stage rounds saw a 25% increase in investment, but early-stage funding suffered, with pre-seed and seed rounds experiencing declines in both capital and deal flow. Ontario led in capital and deal activity, while emerging markets like Manitoba and Nova Scotia posted record investments.
Future Outlook
The latter half of 2025 showed signs of recovery, with increased venture activity and record venture debt levels. However, this activity was concentrated in a few large financings, raising concerns about the broader ecosystem’s health. David Kornacki of CVCA noted that while the increased activity is promising, sustained recovery will require a stronger progression across all financing stages.
As the Canadian VC market looks to 2026, the focus remains on fostering a more balanced ecosystem that supports companies at all stages of growth. The shift towards larger deals poses questions about the long-term health of the startup pipeline, emphasizing the need for diversified investment strategies.
